NFE2L2 and COVID-19: Due to its anti-inflammatory and tissue repair effects, NFE2L2 activation has been recently proposed as a strategy to treat COVID-19 (62), and a clinical trial testing safety, tolerability, and efficacy of Bardoxolone methyl in hospitalized COVID-19 patients was assessed (BARCONA, ClinicalTrials.gov Identifier: NCT04494646).